Physical crystal structures of a compound of the formula (I): are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1) and hydrochloric acid salt Pattern P-5 preferably in substantially pure form and other forms as described herein pharmaceutical compositions containing structures of compound I o...

The disclosure provides compounds of formula I including their salts as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α 7 receptor and may be useful for the treatment of various disorders of the central nervous system especially affective and neurodegenerative disorders.

The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms deep vein thrombosis and acute coronary syndrome with said dosage form.

The disclosure provides compounds of formula I including their salts as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic alpha7 receptor and may be useful for the treatment of various disorders of the central nervous system especially affective and neurodegenerative disorders.

The invention encompasses pharmaceutical compositions and methods for using Compound (1) in combination with other agents for treating patients with AIDS of HIV infection.

Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition such as for example inflammatory disease and pharmaceutical compositions comprising such compounds.

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer an SGLT2 inhibitor formulation as the second layer and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

The disclosure provides compounds of formula I including their salts as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system especially affective and neurodegenerative disorders.